Cancer,
BMC,
Pet,
Sepsis,
Veterinarian,
Death,
Volition,
Neutrophil extracellular traps,
Analyser,
Dog,
Plasma,
Element,
Vaccine HENDERSON, Nev., April 23, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® Vet Cancer Test is now available in-clinic to veterinarians across the U.S and Europe through Antech , a leading veterinary diagnostics company.
Key Points:
- HENDERSON, Nev., April 23, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® Vet Cancer Test is now available in-clinic to veterinarians across the U.S and Europe through Antech , a leading veterinary diagnostics company.
- By incorporating the Nu.Q® Canine Cancer Test into annual checkups or regular senior wellness exams, veterinarians can detect cancer¹ earlier and help pet owners make timely, informed decisions about cancer care."
- Volition's original license and supply agreement was between Belgian Volition SRL and Heska, an Antech company, part of Mars Science & Diagnostics.
- https://doi.org/10.1186/s12917-022-03429-8
According to The Veterinary Cancer Society, one in four dogs will be diagnosed with cancer, and it's the leading cause of death in pets who are beyond middle age.
Conference call,
Volition,
Oncology,
NETS,
ESMO,
Poster,
Blood,
FDA,
Eastern Time Zone,
Neoplasm,
Cryptocurrency HENDERSON, Nev., March 25, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business update for the full fiscal year ended December 31, 2023. Volition management will host a conference call tomorrow, March 26 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.
Key Points:
- Conference call to discuss financial and operational results scheduled for Tuesday, March 26 at 8:30 a.m. U.S. Eastern Time
HENDERSON, Nev., March 25, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business update for the full fiscal year ended December 31, 2023.
- Volition management will host a conference call tomorrow, March 26 at 8:30 a.m. U.S. Eastern Time to discuss these results.
- Cameron Reynolds, President and Group Chief Executive Officer of Volition said: "2023 was certainly transformational for Volition and a year we can look back on with pride.
- Cash and cash equivalents as of December 31, 2023, totaled approximately $20.7 million as compared to $10.9 million as of December 31, 2022.
HENDERSON, Nev. , March 21, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, March 26 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the fourth quarter and full year 2023, in addition to providing a business update. Details of this event can also be found below.
Key Points:
- Details of this event can also be found below.
- The call will provide an update on important events which have taken place in the fourth quarter and full year of 2023 and upcoming milestones.
- A live audio webcast of the conference call will also be available on the investor relations page of Volition's corporate website at https://ir.volition.com .
- The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally.
Retrieved on:
Wednesday, March 20, 2024
HENDERSON, Nev. , March 20, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has agreed a supply agreement with Fujifilm Vet Systems Co. Ltd ("Fujifilm Vet Systems"), a leading veterinary diagnostic laboratory service, to launch the Nu.Q® Vet Cancer Test to veterinarians in Japan.
Key Points:
- HENDERSON, Nev. , March 20, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has agreed a supply agreement with Fujifilm Vet Systems Co. Ltd ("Fujifilm Vet Systems"), a leading veterinary diagnostic laboratory service, to launch the Nu.Q® Vet Cancer Test to veterinarians in Japan.
- Volition's supply agreement enables Fujifilm Vet Systems to sell and perform cancer screening services for dogs using the Nu.Q® Vet Cancer Test throughout its network of central reference laboratories in Japan.
- The Nu.Q® Vet Cancer Test is an accessible and affordable screening tool for dogs to aid in early cancer detection.
- Kiyotaka Fujiwara, Chief Operating Officer at Fujifilm Vet Systems, said: "We are delighted to add the Nu.Q® Vet Cancer Test to our diagnostic service portfolio and expand our wellness testing offer to Japanese veterinarians.
NHS foundation trust,
Thrombosis,
Sepsis,
Guy,
Disease,
Neutrophil extracellular traps,
Consultant,
Patient,
Research,
Intensive care medicine,
Respiratory failure,
ECMO,
NETS,
Cancer,
Heart,
Nursing care plan,
Clinical governance,
Nursing HENDERSON, Nev., March 19, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr Andrew Retter as its Chief Medical Officer, effective April 1, 2024.
Key Points:
- HENDERSON, Nev., March 19, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr Andrew Retter as its Chief Medical Officer, effective April 1, 2024.
- Dr Retter will provide medical leadership at Volition and ensure the company's scientific and clinical efforts are aligned with patient needs.
- Cameron Reynolds, President and Group Chief Executive Officer at Volition, said: "We are delighted to welcome Andrew to Volition.
- As Chief Medical Officer he will be vital to our success – ensuring the needs of the patient are placed at the heart of our research, development and commercialization activities."
Retrieved on:
Tuesday, December 5, 2023
NYSE,
Euro,
NETS,
Sepsis,
Volition (company),
Animal,
Nu,
Diagnosis,
Human,
Pharmaceutical industry,
Security (finance),
Volition HENDERSON, Nev., Dec. 5, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has closed on an aggregate of Euro 5.0 million (approximately $5.5 million) in financing from Wallonie Entreprendre S.A. ("WE") in Belgium.
Key Points:
- HENDERSON, Nev., Dec. 5, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has closed on an aggregate of Euro 5.0 million (approximately $5.5 million) in financing from Wallonie Entreprendre S.A. ("WE") in Belgium.
- Volition is currently working with leading clinicians and researchers at centers of excellence worldwide to help facilitate the effective introduction of Nu.Q® NETs into clinical practice.
- The unsecured loan bears interest at a rate of approximately 8% per year and has a stated maturity date of December 31, 2028.
- This announcement is neither an offer to sell nor a solicitation of an offer to buy any securities.
Retrieved on:
Wednesday, November 8, 2023
HENDERSON, Nev., Nov. 8, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Wednesday, November 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the third quarter 2023, in addition to providing a business update. Details of this event can also be found below.
Key Points:
- Conference call to take place on Wednesday November 15 at 8:30 a.m. U.S Eastern Time
HENDERSON, Nev., Nov. 8, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Wednesday, November 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the third quarter 2023, in addition to providing a business update.
- The call will provide an update on important events which have taken place in the third quarter of 2023 and upcoming milestones.
- A live audio webcast of the conference call will also be available on the investor relations page of Volition's corporate website at https://ir.volition.com .
- In addition, a telephone replay of the call will be available until November 29, 2023.
Veterinarian,
NYSE,
Pet,
Health,
Quality of life,
LLP,
Risk,
Volition,
VPG,
Cancer,
Dog,
Veterinary medicine,
Medical imaging HENDERSON, Nev., Nov. 6, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, and Veterinary Pathology Group (VPG), a leading high quality diagnostic laboratory, have joined forces to launch the Nu.Q® Vet Cancer Test to veterinary practices in the UK and Ireland.
Key Points:
- HENDERSON, Nev., Nov. 6, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, and Veterinary Pathology Group (VPG), a leading high quality diagnostic laboratory, have joined forces to launch the Nu.Q® Vet Cancer Test to veterinary practices in the UK and Ireland.
- VPG is the first-to-market diagnostic laboratory in the UK and Ireland to offer the Nu.Q® Vet Cancer Test, a groundbreaking tool for the early detection and monitoring of cancer in dogs.
- Volition's Nu.Q® Vet Cancer Test is an accessible and affordable screening tool for dogs with increased risk of developing cancer, such as older dogs, certain breeds with higher cancer prevalence rates and those dogs with familial history.
- Dr Tom Butera, Chief Executive Officer, Volition Veterinary Diagnostics Development LLP, said: "Working with VPG, we are thrilled to be rolling out the Nu.Q® Vet Cancer Test to veterinary practices across the UK and Ireland, two renowned pet-loving nations.
Veterinarian,
NYSE,
Pet,
Health,
Quality of life,
LLP,
Risk,
Volition,
VPG,
Cancer,
Dog,
Veterinary medicine,
Medical imaging HENDERSON, Nev., Nov. 6, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, and Veterinary Pathology Group (VPG), a leading high quality diagnostic laboratory, have joined forces to launch the Nu.Q® Vet Cancer Test to veterinary practices in the UK and Ireland.
Key Points:
- HENDERSON, Nev., Nov. 6, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, and Veterinary Pathology Group (VPG), a leading high quality diagnostic laboratory, have joined forces to launch the Nu.Q® Vet Cancer Test to veterinary practices in the UK and Ireland.
- VPG is the first-to-market diagnostic laboratory in the UK and Ireland to offer the Nu.Q® Vet Cancer Test, a groundbreaking tool for the early detection and monitoring of cancer in dogs.
- Volition's Nu.Q® Vet Cancer Test is an accessible and affordable screening tool for dogs with increased risk of developing cancer, such as older dogs, certain breeds with higher cancer prevalence rates and those dogs with familial history.
- Dr Tom Butera, Chief Executive Officer, Volition Veterinary Diagnostics Development LLP, said: "Working with VPG, we are thrilled to be rolling out the Nu.Q® Vet Cancer Test to veterinary practices across the UK and Ireland, two renowned pet-loving nations.
NHS foundation trust,
The Royal Marsden NHS Foundation Trust,
Real-time,
Plasma,
Genomics,
NYSE,
ESMO,
Leukemia,
Biomarker,
Nucleic acid thermodynamics,
Chromatin immunoprecipitation,
Hereditary nonpolyposis colorectal cancer,
Colorectal cancer,
Chromatin,
PCR,
Research,
Science,
Neoplasm,
FIT,
Volition,
Oncology,
Blood,
European Society for Medical Oncology,
Liquid biopsy,
Chemistry,
Royal Marsden Hospital,
Automation,
Translational Genomics Research Institute,
CTCF,
DNA,
Vaccine,
Medical imaging,
Coal,
Cancer Volition has developed a novel method for liquid biopsy involving the first reported physical isolation of a class of tumor-derived ctDNA fragments from blood.
Key Points:
- Volition has developed a novel method for liquid biopsy involving the first reported physical isolation of a class of tumor-derived ctDNA fragments from blood.
- Removal of normal DNA obviates expensive and time-consuming DNA sequencing and bioinformatics allowing for rapid, cost-effective detection in a routine blood test."
- Volition tested the new method in a first small clinical experiment and detected a range of liquid and other cancers, including at early stage I disease.
- Volition has organized a data insights webinar on Thursday 26th October at 10.30 AM U.S. Eastern to provide more information about the new cancer detection method.
